Table 19 List of the final 38 studies
Article | Assessment |
|---|---|
Goldberg RJ. Management of depression in the patient with advanced cancer. JAMA.246(4):373–6, 1981. | Review |
Costa D, Mogos I, Toma T. Efficacy of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica. 72 (suppl. 320): 85–92, 1985. | RCT included in the review |
Mathé G, Lopez MD, Fréchet M, de Vassal F, Brienza S, Gastiaburu J. A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in an oncology service. Biomedicine and Pharmacotherapy.41(1):13–26, 1987. | No double blind RCT |
Maguire P, Hopwood P, Tarrier N, Howell T. Treatment of depression in cancer patients. Acta Psychiatrica Scandinavica Suppl. 320:81–4, 1985. | Antidepressant therapy was administrated together with anxiolytic and supportive psychotherapy |
Evans DL, McCartney CF, Nemeroff CB, Haggerty JJ Jr, Simon JS, Pedersen CA, Holmes V, Droba M, Mason GA, Raft D, et al. Depression in cancer patients. Diagnostic and treatment considerations. North Carolina Medical Journal.49(10):546–8, 1988. | Review |
Silberfarb PM. Psychiatric treatment of the patient during cancer therapy. CA; A Cancer Journal of Clinicians. 38(3):133–7, 1988. | Review |
Evans DL, McCartney CF, Haggerty JJ Jr, Nemeroff CB, Golden RN, Simon JB, Quade D, Holmes V, Droba M, Mason GA, et al. Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosomatic Medicine. 50(1):73–6, 1988. | No control group. |
Van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo controlled study of Mianserin. British Journal of Psychiatry. 169: 440.443, 1996. | RCT included in the review |
Razavi D, Allilaire JF, Smith M, Salimpour A., Verra M, Desclaux B, Saltel P, Piollet I, Gauvain-Piquard A., Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira M, Mesters P, Blin P. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavia. 94: 205–210, 1996. | RCT included in the review |
Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psycho-Oncology. 7: 291–200, 1998 | RCT included in the review |
Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N. Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. The Journal of International Medical Research. 27(6):264–72, 1999. | The efficacy of trazodone cannot be safely proven when it is compared to a benzodiazepine. Depression was not an eligibility criterion. |
Musselmann DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high dose interferone alpha. The New England Journal of Medicine. Vol 344, No 13, 2001 | Prevention study, thus prevention was not an eligibility criterion. |
Pezella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitrptyline. Breast Cancer Research and Treatment. 70: 1–10, 2001 | RCT included in the review |
Passik SD, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Edgerton S, Dugan W. Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients. A demonstration project. Journal of Pain and Symptom Management. 24(3):318–27, 2002. | No RCT. |
Carr D, Goudas L, Lawrence D, Pirl W, Lau J, DeVine D, Kupelnick B, Miller K. Management of cancer symptoms: pain, depression, and fatigue. Evidence Report/Technology Assessment. 61:1–5, 2002. | Review. |
Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Review of Anticancer Therapy. 2(4): 365–76, 2002. | Recommendation |
Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen SH, Arquette MA, Brames MJ, Einhorn LH. Fluoxetine versus Placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier oncology group. Journal of Clinical Oncology. Vol 21, No 10: 1937–1943, 2003. | RCT included in the review |
Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open label pilot study of citalopram for depression and boredom in ambulatory cancer patients. Palliat Support Care. 2003 Mar;1(1):71–7. | No RCT. |
Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ, Hynes HE, Banerjee TK, Kirschner JJ, King DK. Differential effects of paroxetine on fatigue and depression: a randomized, double blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Journal of Clinical Oncology. Vol 21, No 24: 4635–4641, 2003 | Depression was not an eligibility criterion |
Pae CU, Kim YJ, Won WY, Kim HJ, Lee S, Lee CU, Lee SJ, Kim DW, Lee C, Min WS, Kim CC, Paik IH, Serretti A. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Human Psychopharmacology. 19(1):25–9, 2004. | No RCT. |
Coyne JC, Palmer SC, Shapiro PJ. Prescribing antidepressants to advanced cancer patients with mild depressive symptoms is not justified. Journal of Clinical Oncology. 1;22(1):205–6; author reply 206–8, 2004. | Comment. |
Thangathurai D, Roffey P, Mogos M, Riad M, Mikhail M. Usefulness of desipramine in ICU cancer patients for acute depression. Journal of Palliative Care. 20(4):326, 2004. | Comment. |
Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depression and Anxiety. 22(2):94–7, 2005. | No RCT. |
Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazo R, Smith B. Effect of paroxetine hydrochloride on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Research and Treatment. 89: 243–249, 2005. | Depression was not an eligibility criterion. |
Musselmann DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB. A double-blind multicenter parallel-group study of paroxetine, desipramine or placebo in breast cancer patients (stages I, II, III, IV) with major depression. Journal of Clinical Psychiatry. 67: 288–296, 2006. | RCT included in the review. |
Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. The Breast Journal. 12(2):114–22, 2006. | Depression was a secondary outcome. |
Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 15(3):259–67, 2006. | No RCT. |
Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Annals of Oncology. 18(4):689–93, 2007. | No measures for depression were included. |
Stockler MR, O´Connel R, Nowak AK, Goldstein D, Turner J, Wilcken NRC, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo controlled double-blind randomized trial. Lancet Oncology. 8: 603–612, 2007. | Depression was not an eligibility criterion. |
Raji MA, Barnum PD, Freeman J, Markowitz AB. Mirtazapine for depression and comorbidities in older patients with cancer. Annals of Pharmacotherapy.41(9):1548–9, 2007. | No RCT. |
Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Tuhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Supportive Care in Cancer. 16: 1291–1298, 2008. | RCT included in the review. |
Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients. Supportive Care in Cancer. 16(1):83–91, 2008. | No RCT. |
Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y. Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology. 17(2):154–60, 2008. | No RCT. |
Ersoy MA, Noyan AM, Elbi H. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. Clinical Drug Investigation. 28(2):113–20, 2008. | No RCT. |
Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, Yang SJ, Yoon JS. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry and Clinical Neuroscience. 62(1):75–83, 2008. | No RCT. |
Lydiatt WM, Denman D, McNeilly DP, Puumula SE, Burke WJ. A randomized placebo- controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Archives of Otolaryngology- Head and Neck Surgery. Vol. 134 (No 5), 2008. | Prevention study, thus depression was not an eligibility criterion. |
Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Research and Treatment. 112: 197–201, 2008. | RCT included in the review. |
Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. Journal of Palliative Medicine. 13(3):235, 2010. | The authors report on two patients |